Elevance Health

Elevance Health stock surged 2% to $386.89 in pre-market trading but narrowed gains throughout the session, closing at $377.68, down 0.43% from the prior close of $379.31. The intraday swing reflects market ambivalence toward Q2 earnings—while the company beat expectations, concerns about Medicaid margin compression and membership decline sparked a 9% sell-off earlier this month. Recent positive catalysts have offered some stabilization: analysts raised the price target to $393, CEO Gail Boudreaux acquired approximately $1 million of stock, and the company declared a $1.72 quarterly dividend. The stock trades 13.42% below its 52-week high of $436.24, sitting well below its 20-day moving average of $399.69, with a YTD advance of 6.61%. However, underlying earnings momentum remains a concern—Q2 EPS declined 13.08% year-over-year and Q1 fell 16.75%—which may explain the persistent weakness despite management's confidence signals.

Elevance Health (ELV) slid 2.51% to $379.31 today as concerns over Medicaid membership declines and healthcare subsidy margin compression extended post-earnings weakness from last week. Despite second-quarter EPS of $6.71 beating expectations, the revenue-sensitive pressure from policy headwinds reshaped market sentiment. After a modest gain to $390.45 by pre-market 9:29 ET, shares gapped lower at the market open to $384.23, weakening throughout the session to close at $379.31. On a valuation basis, the stock is up 7.07% year-to-date but trades 13.05% below its 52-week high of $436.24, sitting well below the 20-day moving average of $400.17 and approaching the 60-day average of $394.61. Notably, CEO Gail Boudreaux has recently accumulated over $1 million in shares, the company announced a $1.72 dividend, and target price was raised to $393, signaling continued management and analyst confidence in long-term fundamentals, though near-term policy uncertainty and operational risks remain front and center.

Elevance Health slipped 1.1% to $389.09 during regular trading hours, pressured by lingering concerns over Medicaid profitability deterioration disclosed in Q2 results. While revenue rose to $50.47 billion (up 1.4% year-over-year), earnings per share contracted 13.08% year-over-year to $6.71, net income fell 16% sequentially, and Medicaid membership headwinds weighed further on investor sentiment. The stock has retreated 10.81% from its 52-week high of $436.24 achieved on July 14 and currently trades below both the 20-day moving average ($400.40) and 60-day average ($394.22), reflecting technical pressure. However, CEO Gail Boudreaux's recent $1M+ stock purchase, the maintained $1.72-per-share quarterly dividend, and the analyst target price raised to $393 suggest underlying confidence, as near-term weakness may provide relief from earlier profit-taking pressures in what had become an elevated valuation position.

Elevance Health rose 2.17% by close today, with intraday gains reaching roughly 3% before paring in after-hours trading, primarily supported by analysts raising the price target to $393 and improved market sentiment following Q2 earnings. Earlier concerns around healthcare enrollment declines and state-level Medicaid exits had triggered an 8% selloff, which has now been substantially digested. On the earnings front, Q2 revenue of $50.47 billion grew only 1.4% year-over-year, while net profit dropped 16.06% and EPS fell 13.08% year-over-year, signaling persistent margin pressures. Notably, CEO Gail Boudreaux recently purchased approximately $1 million in company stock, signaling management's confidence in long-term prospects. The stock remains roughly 9.81% below its 52-week high of $436, with year-to-date gains of 11.06% and a PE multiple of 17.19 reflecting fair valuation. The recovery appears driven by technical factors, though Medicaid policy dynamics remain a critical variable.

Elevance Health (ELV) gained 2.4% to close at $382.23 today, driven by market recovery from the prior week's earnings-driven selloff. The stock dipped to $376.71 in pre-market trading before rallying sharply to $388.02 intraday, then settling at $382.23, reflecting renewed buying after investors digested Q2's Medicaid membership headwinds and cost inflation. Analysts raised the price target to $393 this week, while CEO Gail Boudreaux also increased her stake by over $1 million, signaling management confidence. Q2 financials revealed revenue of $50.47B (up 1.4% YoY), but EPS fell to $6.71 (down 13.08% YoY) and net profit dropped 16.06% to $1.46B, highlighting the acute pressure from healthcare cost rises. From a valuation lens, the stock is up 7.9% year-to-date and trades 12.38% below its 52-week peak of $436.24, with a market cap near $82.9B. While recent earnings remain under pressure, the analyst target hike suggests conviction in long-term recovery.